Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) has announced a conference call and webcast to discuss its fiscal year 2020 financial results and operational milestones, along with interim data from the MORF-057 Phase 1 clinical trial.

The event is scheduled for March 1, 2021, at 8:00 a.m. Eastern Time. MORF-057 is a selective oral inhibitor focusing on inflammatory bowel disease. Interested parties can access the event via the company's website.

Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the financial results and operational milestones for its fiscal year 2020, ended December 31, 2020. Company management will also discuss interim results from the single ascending dose portion of the ongoing MORF-057 Phase 1 trial. MORF-057 is an oral, selective inhibitor of the α4β7 integrin in clinical development for inflammatory bowel disease. The webcast and conference call will be held at 8:00 a.m. Eastern Time on March 1, 2021.

A live webcast of the call will be available on the Investors section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference call.

To participate in the live conference call, please use the following dial-in information:
US or Canada Toll-Free Dial-In Number: (844) 954-0202
International Dial-In Number: (661) 407-1533
Conference ID: 6992416

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary Morphic Integrin Technology (MInT) Platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397

FAQ

When will Morphic Therapeutic discuss its fiscal year 2020 results?

Morphic Therapeutic will discuss its fiscal year 2020 results during a conference call on March 1, 2021.

What is the purpose of the MORF-057 Phase 1 clinical trial?

The MORF-057 Phase 1 clinical trial is focused on developing an oral selective inhibitor for inflammatory bowel disease.

How can I participate in the Morphic Therapeutic conference call?

To participate, use the US toll-free number (844) 954-0202 or the international number (661) 407-1533 with Conference ID 6992416.

What time is the Morphic Therapeutic conference call scheduled for?

The conference call is scheduled for 8:00 a.m. Eastern Time on March 1, 2021.

Where can I find the webcast for the Morphic Therapeutic call?

The webcast will be available on the Investors section of Morphic Therapeutic's website.